ALK and non-small cell lung carcinoma: Nivolumab is an anti-PD-1 antibody approved with PD-L1 IHC 28-8 pharmDx (independent of PD-L1 status), which is indicated as a first-line treatment for metastatic non-small-cell lung cancer (NSCLC) in patients whose tumors do not have a sensitizing EGFR mutation or ALK translocation, given in combination with ipilimumab and 2 cycles of platinum-based chemotherapy.